Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - BIOLASE, INC | exhibit2.htm |
EX-10.1 - EX-10.1 - BIOLASE, INC | exhibit1.htm |
8-K - LIVE FILING - BIOLASE, INC | htm_55414.htm |
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
IRVINE, CA (October 3, 2017) -BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on October 2, 2017, John R. Beaver, the Companys Senior Vice President and Chief Financial Officer, received a stock option to purchase 600,000 shares of the Companys common stock with an exercise price of $0.59 per share, the closing price per share on October 2, 2017. Of the total 600,000 shares covered by the options, 100,000 shares vest on the one-year anniversary of grant, 300,000 shares vest ratably on a monthly basis over a three-year period after the one-year anniversary of grant, and 200,000 shares vest based on the achievement of certain performance criteria established by the Compensation Committee, subject to Mr. Beavers continued service with the Company through the applicable vesting dates.
The stock options are subject to accelerated vesting upon a termination following a change of control. The stock options were granted outside of the Companys stockholder-approved equity incentive plan and were approved by the Compensation Committee of the Board of Directors, which is comprised of independent directors, as an inducement material to Mr. Beavers entering into employment with the Company, and in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser
systems in dentistry and medicine and also markets, sells, and distributes dental imaging
equipment, including digital x-rays and CAD/CAM scanners. BIOLASEs products are focused on
technologies that advance the practice of dentistry to both dentists and their patients. BIOLASEs
proprietary laser products incorporate approximately 210 patented and 90 patent-pending
technologies designed to provide biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge technology at competitive
prices to deliver the best results for dentists and patients. BIOLASEs principal products are
revolutionary dental laser systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE
has sold approximately 34,900 laser systems to date in over 90 countries around the world. Laser
products under development address BIOLASEs core dental market and other adjacent medical and
consumer markets.
DresnerAllenCaron
Mike Mason (Investors)
mmason@dresnerallencaron.com
212-691-8087
or
Rene Caron (Investors)
rcaron@dresnerallencaron.com
or
Len Hall (Media)
lhall@dresnerallencaron.com
949-474-4300